PSEN1 and Alzheimer disease: The CPO-Aβ17-21P peptide [23] ameliorates AD-related cognitive decline in APPswe/PSEN1dE9 (APP/PS1) transgenic mice by inhibiting Apolipoprotein E (apoE) and Aβ binding, reducing amyloid deposition, and regulating the inflammatory response.